



Search News:

April 23, 2013 06:13 AM Eastern Daylight Time

Alitair Offers Benzonatate Formulation with Rx-to-OTC Switch Potential

MORRISTOWN, N.J.--([BUSINESS WIRE](#))--Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today provided additional details regarding its '398 patent, which will be offered at a sealed bid sale on May 24, 2013. The '398 patent is specific to formulations of benzonatate, which is currently the only non-narcotic prescription cough product available.

Because benzonatate is a potent topical anesthetic, there are significant safety concerns regarding the liquid-filled gel capsules currently available, which can cause numbing or choking if bitten. The Alitair tablet eliminates the potential for numbing, thereby reducing or eliminating the danger of choking. Based on a recent meeting between Alitair and the FDA, this improvement in safety could make the Alitair benzonatate formulation eligible for an Rx-to-OTC switch.

The Alitair '398 patent will be sold at a sealed bid sale on May 24, 2013, at noon. Parties interested in bidding must sign a confidential disclosure agreement, which can be obtained from Chris Finn of Finn, Warnke, and Gayton by emailing cfinn@finnwarnkegayton.com or by calling 781-237-8840.

About Alitair Pharmaceuticals:

Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA™. Other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.

About Finn, Warnke & Gayton, LLP:

Joseph F. Finn, Jr. C.P.A., is the founding partner of Finn, Warnke & Gayton, LLP (www.finnwarnkegayton.com) Certified Public Accountants of Wellesley Hills, Massachusetts. For further information, please contact Chris Finn at 781-237-8840 or cfinn@finnwarnkegayton.com.